Lastly, we demonstrate that in AML cells with a predisposition to developing VEN resistance based on their mutational profile, substitution of VEN with an MCL-1 inhibitor can be used in combination with CTLs to augment AML cell death. This evidence concerns the gene MCL1 and acute myeloid leukemia.